<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314755</url>
  </required_header>
  <id_info>
    <org_study_id>EC.73.03</org_study_id>
    <nct_id>NCT01314755</nct_id>
  </id_info>
  <brief_title>A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer</brief_title>
  <acronym>IMPACTHN</acronym>
  <official_title>A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terrence Jones</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: The peri-operative enteral administration of a proprietary immune-enhancing&#xD;
      feed (IMPACT) will not reduce post-operative infective complications in patients undergoing&#xD;
      major surgery for squamous cell carcinoma of the Head and neck (SCCHN).&#xD;
&#xD;
      Patients who present with SCCHN for whom surgery is the recommended treatment will, assuming&#xD;
      they fulfill the eligibility criteria, be block randomised into a two-group, double-blind&#xD;
      randomised controlled trial. One group will receive IMPACT, the other an iso-caloric,&#xD;
      iso-nitrogenous control feed for 5 days pre and 7 days post-operatively. In both groups&#xD;
      patients will be fed enterally. The feeds will be prepared in identical bottles to facilitate&#xD;
      blinding. Primary outcome measures include major systemic infection, whilst secondary outcome&#xD;
      measures include local infection and length of hospital stay. Follow-up will be for 30 days&#xD;
      postsurgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>either Impact or an iso-nitrogenous, iso-caloric control feed for five days pre and seven days post-surgery</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic infection</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Lower respiratory tract; Gastro-intestinal tract; Urinary tract; Haematological.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local/wound site infection</measure>
    <time_frame>Within 30 days post-surgery</time_frame>
    <description>Local/wound site infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative hospital stay</measure>
    <time_frame>Up to 30 days post surgery</time_frame>
    <description>Length of post-operative hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Squamous Cell Carcinoma of Mouth</condition>
  <condition>Squamous Cell Carcinoma of Oropharynx</condition>
  <condition>Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Hypopharynx</condition>
  <arm_group>
    <arm_group_label>immune-enhancing feed IMPACT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immune-enhancing feed IMPACT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iso-nitrogenous, iso-caloric control feed</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IMPACT</intervention_name>
    <description>IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.</description>
    <arm_group_label>immune-enhancing feed IMPACT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>An iso-caloric, iso-nitrogenous control feed</intervention_name>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who were to undergo either of the following procedures&#xD;
&#xD;
          -  partial (external approach) or total laryngectomy&#xD;
&#xD;
          -  partial pharyngectomy with primary closure or free-flap reconstruction&#xD;
&#xD;
          -  total pharyngectomy (gastric (or colonic) transposition, other free flap&#xD;
             reconstruction, or other pedicled flap reconstruction)&#xD;
&#xD;
          -  oral cavity or oropharyngeal resection requiring reconstruction with a free flap or&#xD;
             pedicled flap&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with&#xD;
&#xD;
          -  malabsorption syndromes&#xD;
&#xD;
          -  primary immune disorders&#xD;
&#xD;
          -  active infection on presentation&#xD;
&#xD;
          -  patients undergoing secondary surgical reconstruction&#xD;
&#xD;
          -  patients undergoing palliative surgery&#xD;
&#xD;
          -  patients aged under 18 years old&#xD;
&#xD;
          -  patients who were pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence M Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.headandneckcancer.co.uk</url>
    <description>Aintree Hospital web site</description>
  </link>
  <link>
    <url>http://www.liv.ac.uk/cancerstudies/CRUK_centre.htm</url>
    <description>Liverpool university web site</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Liverpool University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Terrence Jones</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Head and Neck neoplasm</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Infection</keyword>
  <keyword>Post-operative</keyword>
  <keyword>Surgery</keyword>
  <keyword>Immune-enhancing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

